Published in Medical Letter on the CDC and FDA, September 25th, 2005
SPIRIT III is a large-scale, pivotal clinical trial evaluating XIENCE V, an everolimus- eluting coronary stent system utilizing Guidant's cobalt chromium MULTI-LINK VISION Coronary Stent System platform. This prospective, single-blind trial evaluates the safety and efficacy of XIENCE V compared to the TAXUS Express 2 Paclitaxel Eluting Coronary Stent System for the treatment of coronary artery disease....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.